Abstract
Identifying previously unknown proteins or detecting the presence of known proteins in research samples is critical to many experiments conducted in life sciences, including dermatology. Sensitive protein detection can help elucidate new intervention targets and mechanisms of disease, such as in autoimmune blistering skin diseases, atopic eczema, or other conditions. Historically, peptides from highly purified single proteins were sequenced, with many limitations, by stepwise degradation from the N-terminus to the C-terminus with subsequent identification by UV absorbance spectroscopy of the released amino acids (i.e., Edman degradation). Recently, however, the availability of comprehensive protein databases from different species (derived from high-throughput next-generation sequencing of those organisms’ genomes) and sophisticated bioinformatics analysis tools have facilitated the development and use of mass spectrometry for identification and global analysis of proteins, summarized as mass spectrometry-based proteomics. Mass spectrometry is an analytical technique measuring the mass (m)-to-charge (z) ratio of ionized biological molecules such as peptides. Proteins can be identified by correlating peptide-derived experimental mass spectrometry spectra with theoretical spectra predicted from protein databases. Here we briefly describe how this technique works, how it can be used for identification of proteins, and how this knowledge can be applied in elucidating human biology and disease.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Journal of Investigative Dermatology |
| Jahrgang | 138 |
| Ausgabenummer | 6 |
| Seiten (von - bis) | 1236-1242 |
| Seitenumfang | 7 |
| ISSN | 0022-202X |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 06.2018 |
Fördermittel
This work was supported by grants from the National Institutes of Arthritis, Musculoskeletal and Skin Diseases of the National Institutes of Health (JRS, R01-AR052672), grants from the DFG (CMH and SE, GRK1727), support from the Section of Medicine at the University of Luebeck (J03-2015) to CMH, and National Cancer Institute grant R50CA221838 to H-YT, and support of the Wistar Proteomics and Metabolomics Core Facility was provided by Cancer Center Support Grant CA010815 to the Wistar Institute.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Infektion und Entzündung - Zentrum für Infektions- und Entzündungsforschung Lübeck (ZIEL)
Fingerprint
Untersuchen Sie die Forschungsthemen von „Research Techniques Made Simple: Mass Spectrometry for Analysis of Proteins in Dermatological Research“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver